Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
New CDC report backs COVID vaccine effectiveness in children as vaccine safety probe heats up at FDA
As regulatory uncertainty around COVID vaccines continues to swirl, a new report from the Centers for Disease Control and Prevention (CDC) showcases the benefits of the immunizations among children | ...
European legislators have reached a deal on a major rewrite of the region's pharma policies, pushing forward a framework ...
As it shifts strategic direction to prioritize its recently acquired ENvue feeding tube placement system, NanoVibronix is changing its name to reflect the new focus. | As it shifts strategic direction ...
After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback